Acorah Software Products - Accounts Production 19.4.351 false true false true No description of principal activity 13 February 2025 28 February 2026 28 February 2026 16250118 P A Adu-Yeboah iso4217:GBP iso4217:EUR iso4217:USD xbrli:shares xbrli:pure xbrli:pure 16250118 2025-02-12 16250118 2026-02-28 16250118 2025-02-13 2026-02-28 16250118 frs-core:CurrentFinancialInstruments 2026-02-28 16250118 frs-bus:PrivateLimitedCompanyLtd 2025-02-13 2026-02-28 16250118 frs-bus:FilletedAccounts 2025-02-13 2026-02-28 16250118 frs-bus:Micro-entities 2025-02-13 2026-02-28 16250118 frs-bus:AuditExempt-NoAccountantsReport 2025-02-13 2026-02-28 16250118 frs-bus:Director1 2025-02-13 2026-02-28
Registered number: 16250118
Elanje Pharma Ltd
Unaudited Financial Statements
For the Period 13 February 2025 to 28 February 2026
Statement of Financial Position
Registered number: 16250118
28 February 2026
£
Fixed assets 1,132
Current assets 17,134
Creditors: Amounts Falling Due Within One Year (18,031 )
NET CURRENT LIABILITIES (897 )
TOTAL ASSETS LESS CURRENT LIABILITIES 235
NET ASSETS 235
CAPITAL AND RESERVES 235

Notes

1. General Information
Elanje Pharma Ltd is a private company, limited by shares, incorporated in England & Wales, registered number 16250118 . The registered office is 34 Bank Road, Atherstone, Warwickshire, CV9 1JX.
2. Average Number of Employees
Average number of employees, including directors, during the period was: 2
2
For the period ending 28 February 2026 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The member has not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges her responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.
On behalf of the board
P A Adu-Yeboah
Director
21 October 2026